Zeqmelit® (Dexamethasone oral film)
Severe acute allergic reactions (e.g., anaphylaxis)
Key Facts
About AcuCort
AcuCort is an innovative, publicly traded Swedish pharmaceutical company with a mission to develop and commercialize 'smart drugs' based on existing, well-documented substances. Its core achievement is the approval and ongoing commercialization of Zeqmelit®, a proprietary oral film for acute conditions, now marketed in the Nordics with further registrations pending. The company's strategy is built on a capital-efficient, de-risked model that leverages a robust oral film technology platform to create patient-friendly treatments, which are then brought to market through regional and global licensing partners. This approach aims to deliver significant clinical and patient benefits while optimizing value creation for a company of its size.
View full company profileAbout AcuCort
AcuCort is an innovative, publicly traded Swedish pharmaceutical company with a mission to develop and commercialize 'smart drugs' based on existing, well-documented substances. Its core achievement is the approval and ongoing commercialization of Zeqmelit®, a proprietary oral film for acute conditions, now marketed in the Nordics with further registrations pending. The company's strategy is built on a capital-efficient, de-risked model that leverages a robust oral film technology platform to create patient-friendly treatments, which are then brought to market through regional and global licensing partners. This approach aims to deliver significant clinical and patient benefits while optimizing value creation for a company of its size.
View full company profileAbout AcuCort
AcuCort is an innovative, publicly traded Swedish pharmaceutical company with a mission to develop and commercialize 'smart drugs' based on existing, well-documented substances. Its core achievement is the approval and ongoing commercialization of Zeqmelit®, a proprietary oral film for acute conditions, now marketed in the Nordics with further registrations pending. The company's strategy is built on a capital-efficient, de-risked model that leverages a robust oral film technology platform to create patient-friendly treatments, which are then brought to market through regional and global licensing partners. This approach aims to deliver significant clinical and patient benefits while optimizing value creation for a company of its size.
View full company profileAbout AcuCort
AcuCort is an innovative, publicly traded Swedish pharmaceutical company with a mission to develop and commercialize 'smart drugs' based on existing, well-documented substances. Its core achievement is the approval and ongoing commercialization of Zeqmelit®, a proprietary oral film for acute conditions, now marketed in the Nordics with further registrations pending. The company's strategy is built on a capital-efficient, de-risked model that leverages a robust oral film technology platform to create patient-friendly treatments, which are then brought to market through regional and global licensing partners. This approach aims to deliver significant clinical and patient benefits while optimizing value creation for a company of its size.
View full company profile